OncoBeta ® GmbH Named Among '30 Ethical Companies of the Year 2019' by The Silicon Review Magazine
Recognition for OncoBeta`s mission to give non-melanocytic skin cancer patients back their quality of life.
By: OncoBeta GmbH
"The Silicon Review 30 Ethical Companies of the Year 2019 program identifies companies that are not only financially successful but also are among the most ethical. Winning a spot on this list indicates the company has distinguished itself as an ethically-driven organization,"
"We adhere to a high level of core values in our doings, focusing on providing the best products possible for patients and physicians,"
With the patient in focus, OncoBeta works enthusiastically with medical, scientific, and industrial partners as well as local and national authorities to make his personalized, painless and non-invasive Rhenium-SCT®
The global incidence of non-melanoma skin cancers has been drastically increasing over the past decades. Depending on the source, it is estimated that there are over 5 million non-melanoma skin cancer cases reported globally each year. To serve the increasing medical need for innovative therapies in this field and to improve the quality of patients' lives, OncoBeta® GmbH has developed its innovative Rhenium-SCT®
View the complete list of the Top 30 Ethical Companies 2019 in the digital Silicon Review magazine here:
Read Silicon Review's exclusive interview with Shannon D. Brown III, CEO and Managing Director of OncoBeta GmbH here:
About the Rhenium-SCT®
About OncoBeta® GmbH
OncoBeta® GmbH with its headquarters located at the Garching Technology and Founders Center GATE near Munich, is a privately held medical device company, specializing in the development and commercialization of state-of-the-
Furthermore, having the patient in focus, OncoBeta® is enthusiastically working with medical, scientific and industrial partners as well as local and national authorities to make this personalized, painless and non-invasive therapy accessible to patients all over the world. The Rhenium-SCT®
Find out more about the Rhenium-SCT®
Follow us on social media:
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of OncoBeta®'s control and which could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning OncoBeta®'s plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. OncoBeta® undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.